Blog

  • How the VMAs Became the Red Carpet Home of the Brave

    How the VMAs Became the Red Carpet Home of the Brave

    “The perfect red carpet look is daring, original, and eye-catching. I love a look that references a style or a trend past, but puts a new, fresh spin on it,” says creative director of Off-White and stylist Ib Kamara. And for Kamara, the one artist that consistently hits the mark and gets it right every time is Beyoncé. “She has always been a star, and every time she appears on the red carpet you know she will look flawless,” he adds.

    Having a birds-eye view to the yearly parade of fashion, Lauren Paige—a former publicity co-lead at MTV’s parent company, Paramount—says “you have to bring it!” when stepping onto the VMAs red carpet. Paige worked on the awards show for four years, helping to shape the landscape of the event and escorting talent on the carpet. “The VMAs is the ultimate source for experimental dressing, and is the cultural mecca of awards shows,” Paige says. “When you step onto that carpet, you’re stepping onto historic grounds where some of the world’s most celebrated artists have delivered incredible fashion moments.”

    A VMAs red carpet placement can propel emerging designers and burgeoning brands into fashion world consciousness, especially if worn by the right talent. While the presence of legacy brands and established designers being consistently worn to red carpets is often seen as a ‘safe bet,’ artists at the VMAs have championed their favorites, like Cardi B in Dilara Findikoglu and Olivia Rodrigo in Ludovic de Saint Sernin in 2023.

    Photo: Getty Images

    How the VMAs Became the Red Carpet Home of the Brave

    Photo: Getty Images

    Celebrity and editorial fashion stylist Joiee Thorpe believes brands like Versace remain a top choice for the VMAs because “it’s a sexy brand that has become a red carpet staple.” The likes of Dolce & Gabbana, Mugler, Balmain, and Gucci remain fixtures because, as celebrity fashion stylist Aaron Hawkins says, “these brands are built on drama, sex, and spectacle. And that’s exactly what the VMAs demand.”

    And the glam has to match, of course. Ngozi Olandu Young, an Emmy-nominated and two-time NAACP Image Award-winning makeup artist for film and television, believes that Lil’ Kim is the epitome of this standard, nailing it with her groundbreaking 1999 ensemble. “Lil’ Kim’s one-shoulder purple jumpsuit—with the unforgettable pastie—along with a matching lavender wig, frosted lips, and eye shadow was a full color story ahead of its time,” says Young. “It was more than shock value, but about ownership of her femininity; and it opened the door for the unapologetic freedom of self-expression we celebrate at the VMAs each year.”

    So, what does it take to truly create a memorable VMAs red carpet moment? It requires a look that is equally “daring, sculptural, and deeply personal,” says shoe designer Thom Solo, whose high heels have stomped across red carpets, stages, and music video sets on the feet of Lady Gaga, Doechii, Lana Del Rey, and more. Solo believes that a show-stopping ensemble should “feel like wearable art, a fusion of architecture, craftsmanship, and storytelling.”

    “The VMAs are not as conventional or conservative as the other awards ceremonies,” affirms Solo, “so there’s freedom to play a little—or should I say, a lot!”

    Following its high-octane 40th anniversary last year, the VMAs are returning to New York once again. The 2025 awards show will see nominees including Lady Gaga, Sabrina Carpenter, The Weeknd, Kendrick Lamar, Billie Eilish, and more deliver another round of memorable red carpet moments. Ahead of the 2025 VMAs, here’s a look back at 15 of the most fascinating and thought-provoking VMAs red carpet looks throughout the years—in no particular order:


    Continue Reading

  • US independent director Jim Jarmusch triumphs at Venice Festival – Reuters

    1. US independent director Jim Jarmusch triumphs at Venice Festival  Reuters
    2. ‘Father Mother Sister Brother’ Review: Jim Jarmusch’s Wry Triptych  IndieWire
    3. Beloved Singer-Songwriter, 75, Is Starring as Adam Driver’s On-Screen Father in New Film  parade.com
    4. Family Relations Get Toasted and Roasted in Teaser for Jim Jarmusch’s ‘Father Mother Sister Brother’  The Hollywood Reporter
    5. ‘Father Mother Sister Brother’ Wins Golden Lion at the Venice Film Festival Awards  Yahoo News Canada

    Continue Reading

  • AP-101 Meets Primary End Point in Phase 2 Study of SOD1 ALS

    AP-101 Meets Primary End Point in Phase 2 Study of SOD1 ALS

    According to a new announcement, AL-S Pharma’s AP-101, a monoclonal antibody targeting misfolded SOD1, met its primary safety and tolerability end point in a phase 2 study of both patients with sporadic amyotrophic lateral sclerosis (ALS) and mutant SOD1-ALS. The company is planning to present the full data at upcoming scientific conferences, as well as engage with regulatory authorities later this year on determining next steps for this agent.1

    This randomized, double-blind, placebo-controlled trial included 52 patients with sporadic ALS and 21 patients with SOD1-ALS who were evaluated for a 24-week treatment period, followed by a 24-week open-label extension and a safety follow-up period. While no specifics of the data were released, AL-S Pharma noted that the drug was safe, and led to clinically meaningful changes in outcome measures and stabilization of relevant biomarkers.

    To date, tofersen (Qalsody; Biogen) remains the only FDA-approved treatment for patients with SOD1-ALS, which make up about 15-20% of familial ALS cases and roughly 2% of all ALS cases overall. AP-101, discovered using Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology, is designed to selectively bind to misfolded and aggregated forms of SOD1, leaving the normal SOD1 untouched. This targeted binding is intended to promote clearance–likely via phagocytosis–of the pathological proteins, potentially slowing motor neuron death.

    “We are excited by the topline Phase 2 results of AP-101 for ALS, a devastating degenerative disease for which new treatments are urgently needed,” Michael Salzmann, PhD, chief executive officer at AL-S Pharma, said in a statement. “We are grateful to the participants, their families and the international network of ALS experts who made this trial possible, and we look forward to sharing results from the study at the International Symposium on ALS/MND.”

    READ MORE: Amylyx Discontinues AMX0035 Program in Supranuclear Palsy Following Disappointing Phase 2b Data

    Topline results from the study are expected to be presented at the 36th International Symposium on ALS/MND on December 5, 2025, while he baseline characteristics and analysis of misfolded SOD1 target levels are expected at the 2025 Annual NEALS Meeting. The phase 2 study, which began in 2021, primarily focused on safety and tolerability, but also included other outcomes such as half-life, area under the drug concentration, cerebrospinal fluid (CSF) levels in neurofilament light and phosphor-neurofilament heavy chain levels.

    The phase 2 study included those with ALS whose symptoms began within the past 24 months, while having documented progressive motor impairment and evidence of motor neuron dysfunction. Those with familial cases required a confirmed pathogenic SOD1 mutation to be included.

    Additional requirements for the study included an SVC greater than 50, limited ventilatory support use, stable riluzole or edaravone regimens if spplicable, adequate venous access, and acceptable lablvalues. Exclusions applied to those recently in other trials, requiring tracheostomy or at least 4 hours/day of noninvasive ventilation, with other causes of neuromuscular weakness, significant comorbidities, pregnancy or nursing, prior SOD1 antisense therapy within six months, or prior stem cell therapy.

    “This is the first Phase 2 study to assess a SOD1-targeted therapeutic in both sporadic ALS and in ALS patients with mutations in the SOD1 gene. The study allowed us to rigorously assess patient safety, pharmacokinetics, and early signals of biological activity,” Principal investigator Peter Anderson, PhD, professor and senior consultant neurologist at Umea University, in Sweden, said in a statement. “The completion of the trial marks an important step in evaluating the therapeutic potential of AP-101 for broad use in patients with ALS. The results support the hypothesis that misfolded SOD1 protein plays a more general role in ALS.”

    REFERENCES
    1. AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS). News release. AL-S Pharma. September 4, 2025. Accessed September 4, 2025. https://www.prnewswire.com/news-releases/al-s-pharma-announces-positive-topline-results-from-phase-2-study-of-ap-101-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-302545686.html

    2. A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS). Clincialtrial.gov. Updated August 19, 2025. Accessed September 4, 2025. https://clinicaltrials.gov/study/NCT05039099, in Sweden, said in a statement. “The completion of the trial marks an important step in evaluating the therapeutic potential of AP-101 for broad use in patients with ALS. The results support the hypothesis that misfolded SOD1 protein plays a more general role in ALS.”

    REFERENCES
    1. AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS). News release. AL-S Pharma. September 4, 2025. Accessed September 4, 2025. https://www.prnewswire.com/news-releases/al-s-pharma-announces-positive-topline-results-from-phase-2-study-of-ap-101-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-302545686.html
    2. A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS). Clincialtrial.gov. Updated August 19, 2025. Accessed September 4, 2025. https://clinicaltrials.gov/study/NCT05039099

    Continue Reading

  • Collaborative Strategies to Enhance Care and Data Sharing in LGS

    Collaborative Strategies to Enhance Care and Data Sharing in LGS

    WATCH TIME: 3 minutes | Captions are auto-generated and may contain errors.

    Lennox-Gastaut syndrome (LGS) is a rare epilepsy syndrome that typically begins in childhood and is associated with frequent seizures, cognitive impairment, and long-term disability. Earlier this summer, the LGS Foundation hosted its 3rd biennial LGS Research Meeting of the Minds, held July 21–22, 2025, bringing together caregivers, researchers, health care providers, scientists, advocacy representatives, and industry partners to discuss clinically relevant strategies to advance evidence-based LGS care across the lifespan.

    In collaboration with LGS Foundation, NeurologyLive® held a roundtable discussion with 2 pediatric experts who attended and participated in the meeting. Throughout the panel discussion, the duo covered topics like major gaps in LGS care, fostering connections among diverse stakeholders, and shaping strategies to guide future research. The guests featured in this panel included Scott Perry, MD, head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center, and Gita Gupta, MD, MS, assistant professor of pediatrics at the Johns Hopkins University.

    In this second episode, clinicians commented on leveraging existing resources, including the LGS Foundation and the Pediatric Epilepsy Research Consortium (PERC), to standardize clinical data collection and improve comparative effectiveness research in LGS. Experts noted that plans include expanding the LGS patient registry, developing consensus treatment guidelines, and engaging parents as active data stewards through third-party tools that organize and share medical information. The duo underscored that these coordinated efforts aim to improve care delivery, optimize treatment selection, and advance research for the LGS community.

    Transcript edited for clarity. Click here to view more content of the LGS Foundation.

    Isabella Ciccone, MPH: Now that we’ve talked a little bit about the gaps in care, my next question is, what are some actionable strategies proposed during the meeting that can improve care delivery or outcomes for patients with LGS?

    Scott Perry, MD: Yeah. So, just to get back to the gap that I brought up, one of the actionable items is using the resources we have. We’ve got a few really good resources at our disposal with the LGS Foundation. One is that the LGS Foundation has been working fairly closely with PERC, which has an LGS special interest group. That group includes multiple investigators across multiple institutions, who we believe could set up a framework for collecting clinical data in a fairly standardized way. This might allow us to do comparative effectiveness studies to understand which medicines may work better in certain situations, just through the natural history of the way we practice medicine—because we all practice slightly differently and have different medicines that are our preferred first lines—and then we’d be able to compare.

    While that’s not a defined and absolute protocol yet, one of the ideas that came out of it is that we could begin collecting data just during our daily clinical care, writing notes in a similar format. That’s a big step to get people to agree to. That was one thing. The LGS Foundation already has a patient registry that has gotten started, and we talked about expanding upon that to continue collecting more information about what medications patients are using, because that will be another data source we can use.

    There are also several groups. There’s an international group with the International League Against Epilepsy (ILAE), as well as PERC, which is also working on a North American consensus on the treatment of LGS. That will be another source to, if nothing else, give us a foundation of where we start from to then compare.

    Gita Gupta, MS, MS: And there was also a call to action for parents to be more mindful—or they’re already very mindful stewards of their children’s data—but to use third-party commercial companies that are helping parents organize their children’s medical information and synthesize it in a way that is interpretable to a nonmedical person. It was interesting to see that these groups empower parents to share their children’s data with different researchers and organizations that are trying to help children with LGS.

    Continue Reading

  • Production Cuts At Major Uranium Mines Help URNJ (NASDAQ:URNJ) – Seeking Alpha

    1. Production Cuts At Major Uranium Mines Help URNJ (NASDAQ:URNJ)  Seeking Alpha
    2. Uranium shortfall threatens nuclear energy renaissance, industry warned  Financial Times
    3. World Nuclear Fuel Report 2025: Investment in nuclear fuel cycle needed as demand for nuclear power grows  World Nuclear Association
    4. Uranium Production Cuts and ETF Opportunities: Why URNJ is Poised for Outperformance  AInvest
    5. Shortage from 2030? Uranium Demand Skyrockets – 30% Increase in just Five Years  GOLDINVEST

    Continue Reading

  • List of winners at the 2025 Venice Film Festival – Reuters

    1. List of winners at the 2025 Venice Film Festival  Reuters
    2. Venice Film Festival Takeaways: Politics Take Spotlight, Oscar Buzz and Apocalyptic Weather  Variety
    3. Toni Servillo, Xin Zhilei win top actors’ awards at Venice  Reuters
    4. See Who Wins at the 2025 Venice Film Festival (Updating List)  IndieWire
    5. Italy Venice Film Festival Awards Ceremony  guardonline.com

    Continue Reading

  • GlocalMe Delivers Award-Winning Innovative Real-World Connectivity Solutions at IFA 2025

    GlocalMe Delivers Award-Winning Innovative Real-World Connectivity Solutions at IFA 2025

    BERLIN, Sept. 6, 2025 /PRNewswire/ — At IFA 2025, GlocalMe, the global connectivity brand under uCloudlink Group Inc. (NASDAQ: UCL), introduced its 3-3-5 Digital Inclusion Framework, a comprehensive strategy designed to eliminate the world’s most persistent digital divides through actionable innovation and market-ready products.

    The framework is built around closing 3 core digital gaps: those between carrier networks, between local and international users, and between people and pets. It is powered by 3 breakthrough technologies, CloudSIM®, AI HyperConn®, and 6-Layer Precision Positioning, and delivered through 5 innovative product lines already available to consumers worldwide.

    These product lines are:

    • Pet Network, led by the award-winning PetPhone—the first smartphone for pets, which has won IFA2025 Innovative Honoree and Yanko Design’s – The Best of IFA2025
    • Personal Mobile Network, featuring eSIM Trio—the first universal SIM for iOS and Android
    • Travel Network, featuring high-performance hotspots including Numen Air (the world’s first SIM-free 5G mobile hotspot), MeowGo G40 Pro (a multi-travel/life setting device for in-flight and home use with unified account access and offers better network with cost-effective solutions), which was given IFA25 Innovative Award by SlashGear, and G50 Pro (incorporating satellite connectivity for comprehensive air-to-ground network coverage)
    • Life Network, offering multi-functional Hotspot-enabled devices such as UniCord Pro and RoamPlug. In that, UniCord Pro was double winner of Tusted Review as the Best In Show Award, and Yanko Design’s – The Best of IFA2025.
    • Home Network, including GuardFlex Pro (5G) for uninterrupted internet access, with expanding IoT applications across smart cameras, in-vehicle systems, and more

    Each product reflects GlocalMe’s dual approach to connectivity: offering high-performance 5G where available while maintaining inclusive 4G coverage so no one is left offline. AI HyperConn® technology plays a key role across these devices—intelligently integrating satellite, in-flight cabin, terrestrial, Wi-Fi (both paid and free), and cellular networks (4G/5G) access to form a high-performance yet cost-effective connectivity solution.

    “For over a decade, we’ve turned vision into reality,” said Jeff Chen, CEO of uCloudlink. “This framework isn’t theoretical—it’s a practical roadmap used to develop products that matter.”

    With its innovative products already driving growth in multiple billion-dollar markets, GlocalMe is demonstrating that inclusive connectivity isn’t just a mission—it’s a measurable reality.

    Experience GlocalMe’s connected future at IFA 2025, Booth H3.2-171, Messe Berlin from September 5-9.

    About GlocalMe
    GlocalMe is a digital lifestyle brand under uCloudlink Group Inc. (NASDAQ: UCL), dedicated to bridging digital divides—including the one between people and their pets—through patented technology and love-centered design. By enabling seamless emotional connections across species and geographies. Its products deliver seamless, affordable mobile internet across more than 200 countries and regions.

    SOURCE uCloudlink Group Inc.

    Continue Reading

  • The Ivalice Chronicles team had to remake the original Final Fantasy Tactics’ source code from scratch

    The Ivalice Chronicles team had to remake the original Final Fantasy Tactics’ source code from scratch

    The Square Enix team behind Final Fantasy Tactics — The Ivalice Chronicles didn’t just remaster the iconic strategy RPG, they had to go through the trouble of remaking the source code from scratch, according to Bloomberg. In an interview with Bloomberg‘s Jason Schreier, the game’s director Kazutoyo Maehiro explained the arduous process of designing The Ivalice Chronicles, which is set to release at the end of the month.

    When getting to work on the remake, Maehiro and his team discovered they had to rebuild the source code from the ground up since it was lost thanks to the industry’s unstandardized practices in the ’90s, according to Bloomberg. When translating Final Fantasy Tactics from Japanese to English for the global release, the company would overwrite the original Japanese version’s code. For Maehiro, that meant the team had to undertake a ground-up overhaul and recreate the source code by playing the original game that released in 1997, consulting the game’s master disc and looking at the 2011 version called Final Fantasy Tactics: The War of the Lions, according to Bloomberg. Maehiro also said during a PAX West 2025 panel that the team gleaned a lot of lost info from fan-made databases.

    Revealing more of the behind-the-scenes decisions for The Ivalice Chronicles, Maehiro told Bloomberg about the debate surrounding Count Cidolfus Orlandeau. Better known as Cid, and appropriately nicknamed Thunder God Cid, this overtuned character joins you later in the game, but many fans complained about him being overpowered. Instead of nerfing Cid, Maehiro told Bloomberg that keeping this character’s power level the same would better represent the storyline since “his role in the story is being that very powerful character who joins your party.” To quell any concerns of Cid being too broken, Maehiro told Bloomberg that the team decided to buff the other characters to even things out. Looking ahead, Maehiro also hinted at exploring sequels for the Final Fantasy Tactics franchise or even brand new games in the strategy RPG genre, given that The Ivalice Chronicles does well, according to Bloomberg.

    Continue Reading

  • 5-Day High-Protein, High-Fiber Meal Plan

    5-Day High-Protein, High-Fiber Meal Plan

    Meal Plan at a Glance
    Breakfast/ A.M. Snack Lunch/ P.M. Snack Dinner/ Evening Snack
    Blueberry & peanut chia pudding/ Hard-boiled egg & nuts High-protein black bean salad Charred shrimp pesto bowls/ Dark chocolate
    Blueberry & peanut chia pudding Marry Me white bean salad/ Edamame Crispy salmon bowl/ Chai energy balls
    Black bean & cheese quiche/ Apple High-protein black bean salad Taco-stuffed sweet potato/ Yogurt parfait
    Black bean & cheese quiche/ Apple & nut butter Chopped Cobb salad Chicken & broccoli pasta/ Chai energy balls
    Black bean & cheese quiche/ Yogurt parfait Chopped Cobb salad/ Edamame Turkey fajita bowls

    Day 1

    Charred Shrimp, Pesto & Quinoa Bowls.

    Breakfast (478 Calories) 

    Morning Snack (181 Calories) 

    Lunch (596 Calories)

    Dinner ( 429 Calories)

    Evening Snack ( Calories) 

    • 1 oz. dark chocolate (70-85%)  

    Daily totals:  1,803 calories, 97 g fat, 90 g protein, 161 g carbohydrates, 52 g fiber, 1,821 mg sodium

    To make it 1,500 calories:  Omit morning snack and evening snack. Add  ¼ cup scrambled egg whites to breakfast. 

    To make it 2,000 calories: Add 1 serving Everything Bagel Cottage Cheese Snack Jar with Bell Peppers & Chickpeas to afternoon snack.

    Day 2

    Chai Energy Balls.

    Photographer: Stacy Allen, Food Stylist: Chelsea Zimmer, Prop Stylist: Christina Daley


    Breakfast (478 Calories) 

    Lunch (379 Calories)

    Afternoon Snack (224 Calories) 

    • 1¼ cups frozen edamame (in pods), warmed

    Dinner (526 Calories)

    Evening Snack ( 206 Calories) 

    Daily totals: 1,812 calories, 91 g fat, 102 g protein, 176 g carbohydrates, 48 g fiber, 1,093 mg sodium

    To make it 1,500 calories:  Reduce afternoon snack portion of edamame to ¾ cup and omit evening snack. 

    To make it 2,000 calories: Add 1 serving Everything Bagel Cottage Cheese Snack Jar with Bell Peppers & Chickpeas to morning snack.

    Day 3

    Black Bean & Pepper Jack Quiche.

    Photographer: Jen Causey, Food Stylist: Emily Nabors Hall, Prop Stylist: Julia Bayless.


    Breakfast (332 Calories)

    Morning Snack (78 Calories) 

    Lunch (596 Calories)

    Dinner (510 Calories)

    Evening  Snack ( 301 Calories) 

    Daily totals: 1,815 calories, 83 g fat, 97 g protein, 186 g carbohydrates, 45 g fiber, 1,737 mg sodium.

    To make it 1,500 calories:  Omit evening snack.

    To make it 2,000 calories: Add 1 serving Everything Bagel Cottage Cheese Snack Jar with Bell Peppers & Chickpeas to afternoon snack. 

    Day 4

    Chopped Cobb Salad.

     Breakfast (332 Calories)

    Morning Snack ( 268 Calories) 

    • 1 small apple + 2 Tbsp. natural peanut butter 

    Lunch ( 481 Calories) 

    Dinner (530 Calories) 

    Evening Snack ( 206 Calories) 

    Daily totals: 1,816 calories, 82 g fat, 94 g protein, 195  g carbohydrates, 38 g fiber, 1,428 mg sodium

    To make it 1,500 calories: Reduce to 1 Tbsp. peanut butter at morning snack. Omit evening snack. 

    To make it 2,000 calories: Add 1 serving Everything Bagel Cottage Cheese Snack Jar with Bell Peppers & Chickpeas to afternoon snack. 

    Day 5

    Ground Turkey Rice Bowl.

    Photographer: Jen Causey, Food Stylist: Margaret Monroe Dickey, Prop Stylist: Hannah Greenwood.


    Breakfast (332 Calories)

    Morning Snack ( 301 Calories) 

    Lunch ( 481 Calories) 

    Afternoon Snack (135 Calories) 

    • ¾ cup frozen edamame (in pods), warmed

    Dinner (570 Calories)

    Daily totals:  1,818 calories,  74 g fat, 110 g protein, 202 g carbohydrates, 40 g fiber,  1,501 mg sodium

    To make it 1,500 calories:  Omit morning snack. 

    To make it 2,000 calories: Add 1 oz. dark chocolate (70-85%) and 1 Tbsp. almonds to evening snack. 

    Frequently Asked Questions


    • Is it OK to mix and match meals if there’s one I don’t like?

      Yes! This meal plan is meant to serve as inspiration. It doesn’t need to be followed exactly to reap the benefits. When choosing recipes, we made sure to check the calories, fiber, protein and sodium to align with the parameters of this plan and be within our sodium limits. If you’re making a recipe swap, it may be helpful to choose a recipe with similar calories, fiber, protein and sodium levels. For more inspiration, check out these delicious High-Protein, High-Fiber Dinners That Are Easy to Make.


    • Can I eat the same breakfast or lunch every day?

      Definitely, it’s fine to eat the same breakfast or lunch every day. The breakfasts range from 332 to 478 calories, while the lunches span 379 to 596 calories. These ranges are fairly close, though if you’re closely monitoring your calories or other nutrients, like protein, you may want to adjust a snack or two.


    • Why is there not a 1,200-calorie modification?

      We no longer provide modifications for 1,200-calorie days in our meal plans. The 2020-2025 Dietary Guidelines for Americans suggests that limiting calories to 1,200 per day is too low for most people to meet their nutritional needs, plus it’s unsustainable for long-term health and well-being.

    Health Benefits of a High-Protein, High-Fiber Diet

    Protein is found in every cell in our body. Because of this, it’s essential for countless bodily functions like bone and muscle health, digestion and energy production. While most people get enough protein, certain factors like activity level, age or health goals may amp up your needs. 

    On the flip side, diets that are too high in protein can sometimes lack fiber, which may lead to digestive troubles. Striking the right balance of both protein and fiber is key to keeping your body healthy and running smoothly. Fiber brings its own powerful set of benefits. Diets rich in fiber have been linked to healthier weight loss and long-term weight control, a lower risk of type 2 diabetes and heart disease, reduced odds of certain cancers, more regular bowel movements and even a longer life. 

    Together, protein and fiber help you feel full and satisfied after meals, support digestion and keep your energy steady throughout the day. Talk about a winning combo for health and well-being! 

    How We Create Meal Plans

    Registered dietitians thoughtfully create EatingWell’s meal plans to be easy-to-follow and delicious. Each meal plan meets specific parameters depending on the health condition and/or lifestyle goal it is targeting and is analyzed for accuracy using the nutrition database, ESHA Food Processor. As nutritional needs differ from person to person, we encourage you to use these plans as inspiration and adjust as you see fit.

    Dig Deeper

    The 7 Best High-Protein Foods to Eat as Snacks, According to Dietitians

    9 Out of 10 Americans Don’t Get Enough Fiber—Here’s How Much You Really Need

    Continue Reading

  • $40 Million Raised To Bring Traditional Financial Institutions Onto Ethereum

    $40 Million Raised To Bring Traditional Financial Institutions Onto Ethereum

    Etherealize, a company focused on building the infrastructure needed to bring traditional financial institutions onto Ethereum, has closed a $40 million funding round led by Electric Capital and Paradigm. This new investment follows a foundational grant from Ethereum co-founder Vitalik Buterin and the Ethereum Foundation in 2024, which helped launch the company’s operations and early outreach to the financial sector. With this latest round, Etherealize is entering a new phase of growth, deepening its role as a key architect of institutional-grade tools for tokenized assets and privacy-preserving settlement on Ethereum.

    The company’s mission is ambitious but clear: to modernize the legacy financial system by integrating it with Ethereum’s programmable, decentralized infrastructure. Etherealize is developing a suite of technologies specifically designed for institutional use, including a zero-knowledge privacy infrastructure for secure trading and settlement, a settlement engine tailored to the workflows of tokenized assets, and applications that bring liquidity and utility to tokenized fixed-income markets. These tools are not just technical upgrades—they are designed to reshape how institutions interact with digital assets, making Ethereum a viable and compelling foundation for the next generation of financial services.

    Etherealize was founded by a team with deep roots in both traditional finance and the Ethereum ecosystem. Vivek Raman, a former Wall Street trader, brings firsthand experience of institutional workflows and market structure. Danny Ryan, previously a research lead at the Ethereum Foundation, contributes a deep understanding of Ethereum’s technical roadmap and governance. Grant Hummer and Zach Obront round out the founding team with years of experience building in the Ethereum space. Together, they’ve assembled a group of experts that includes veterans from Goldman Sachs, JPMorgan, Lehman Brothers, and top cryptography engineers, all working toward the same goal: to make Ethereum the backbone of institutional finance.

    Since its launch in January 2025, Etherealize has made rapid progress. The team has engaged with hundreds of banks, asset managers, and payment networks, helping shape product development and educate stakeholders about Ethereum’s capabilities. They’ve worked with asset managers to bring new tokenized assets on-chain and supported Layer-2 blockchains in scaling adoption. Their research has helped shift the narrative around Ethereum, positioning it as a credible reserve asset and a foundation for institutional treasury strategies. Etherealize has also played a role in shaping policy, contributing to regulatory discussions and testifying before Congress on digital asset legislation.

    Ethereum itself has matured into a global financial infrastructure layer, processing the vast majority of stablecoin volume and tokenized real-world assets. Its appeal to institutions continues to grow, with major players like JPMorgan, Apollo, Deutsche Bank, Fidelity, BlackRock, and UBS exploring or actively using Ethereum-based solutions. Etherealize is building the connective tissue that enables these institutions to transition from experimentation to full-scale adoption, providing tools that meet their standards for security, compliance, and performance.

    How the funding will be used: The new funding will allow Etherealize to accelerate development, expand its team, and deepen its relationships across Wall Street and the broader financial ecosystem. The company is focused not just on building technology, but on creating a bridge between two worlds that have historically operated in parallel. By aligning Ethereum’s open, programmable infrastructure with the needs of regulated institutions, Etherealize is helping to unlock a new era of financial innovation—one where transparency, efficiency, and global accessibility are no longer trade-offs, but core features.

    KEY QUOTES:

    “Over the past decade, Ethereum has gone from an experiment to the world’s most battle-tested, open financial network. This raise kicks off the ‘Institutional Merge’—upgrading institutional finance to modern, safer, globally accessible rails.”

    Danny Ryan, cofounder and President of Etherealize

    “After hundreds of conversations with banks and institutions, one thing is clear: the future of finance will be built on Ethereum. This funding allows us to accelerate the development of institutional-grade infrastructure that rewires Wall Street with Ethereum as its invisible backbone. We’re proud to not only be a leading voice for Ethereum on Wall Street, but to also be an engineering powerhouse driving the next wave of institutional blockchain adoption.”

    Vivek Raman, CEO of Etherealize

    Continue Reading